1. Home
  2. LEE vs SCYX Comparison

LEE vs SCYX Comparison

Compare LEE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEE
  • SCYX
  • Stock Information
  • Founded
  • LEE 1890
  • SCYX 1999
  • Country
  • LEE United States
  • SCYX United States
  • Employees
  • LEE N/A
  • SCYX N/A
  • Industry
  • LEE Newspapers/Magazines
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEE Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • LEE Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • LEE 33.8M
  • SCYX 32.3M
  • IPO Year
  • LEE N/A
  • SCYX 2014
  • Fundamental
  • Price
  • LEE $4.23
  • SCYX $0.66
  • Analyst Decision
  • LEE
  • SCYX Strong Buy
  • Analyst Count
  • LEE 0
  • SCYX 1
  • Target Price
  • LEE N/A
  • SCYX $3.00
  • AVG Volume (30 Days)
  • LEE 33.0K
  • SCYX 573.5K
  • Earning Date
  • LEE 12-11-2025
  • SCYX 11-13-2025
  • Dividend Yield
  • LEE N/A
  • SCYX N/A
  • EPS Growth
  • LEE N/A
  • SCYX N/A
  • EPS
  • LEE N/A
  • SCYX N/A
  • Revenue
  • LEE $581,809,000.00
  • SCYX $3,257,000.00
  • Revenue This Year
  • LEE N/A
  • SCYX $20.23
  • Revenue Next Year
  • LEE N/A
  • SCYX $933.90
  • P/E Ratio
  • LEE N/A
  • SCYX N/A
  • Revenue Growth
  • LEE N/A
  • SCYX N/A
  • 52 Week Low
  • LEE $3.79
  • SCYX $0.65
  • 52 Week High
  • LEE $19.37
  • SCYX $1.49
  • Technical
  • Relative Strength Index (RSI)
  • LEE 40.61
  • SCYX 28.92
  • Support Level
  • LEE $4.40
  • SCYX $0.68
  • Resistance Level
  • LEE $4.97
  • SCYX $0.82
  • Average True Range (ATR)
  • LEE 0.35
  • SCYX 0.05
  • MACD
  • LEE 0.01
  • SCYX -0.01
  • Stochastic Oscillator
  • LEE 35.09
  • SCYX 4.07

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: